Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive Ibuprofen for XDR Tuberculosis
NCT02781909Phase 2Completed
- Sponsor
- Germans Trias i Pujol Research Institute
- Start
- Sep 2016
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised trial of ibuprofen in Tuberculosis (TB) (2 arms), sponsored by Germans Trias i Pujol Research Institute. Primary endpoints: Number of participants with microbiological efficacy-related events at 6 months, Number of participants with radiological efficacy-related events at 6 months and 2 more. Started Sep 2016; status: completed.
02
Drugs
ibuprofen
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02781909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02781909.